csirt@kutim:~/threat-intel/cve/CVE-2020-29482

Katalog CVE

CVSS 6.0 · Medium EPSS 0,39%

Kerentanan Untrusted Search Path pada xen, debian linux +1 lainnya. Skor CVSS 3.1 6.0 (Medium) menurut NVD.

Deskripsi (NVD)

An issue was discovered in Xen through 4.14.x. A guest may access xenstore paths via absolute paths containing a full pathname, or via a relative path, which implicitly includes /local/domain/$DOMID for their own domain id. Management tools must access paths in guests' namespaces, necessarily using absolute paths. oxenstored imposes a pathname limit that is applied solely to the relative or absolute path specified by the client. Therefore, a guest can create paths in its own namespace which are too long for management tools to access. Depending on the toolstack in use, a malicious guest administrator might cause some management tools and debugging operations to fail. For example, a guest administrator can cause "xenstore-ls -r" to fail. However, a guest administrator cannot prevent the host administrator from tearing down the domain. All systems using oxenstored are vulnerable. Building and using oxenstored is the default in the upstream Xen distribution, if the Ocaml compiler is available. Systems using C xenstored are not vulnerable.

Rincian

Terbit di NVD
15 Desember 2020
Terakhir diubah
17 Juni 2026
Status NVD
Modified
CVSS 3.1
6.0 (Medium), sumber NVD
CVSS:3.1/AV:L/AC:L/PR:H/UI:N/S:C/C:N/I:N/A:H · uraikan di kalkulator
Jenis kelemahan (CWE)
CWE-426: Untrusted Search Path
EPSS (30 hari)
0,39% peluang dieksploitasi; lebih tinggi dari 31,2% CVE lain

Produk dan versi terdampak

VendorProdukVersi terdampak
xen xen Semua versi hingga 4.14.0
debian debian linux Versi 10.0
fedoraproject fedora Versi 32
fedoraproject fedora Versi 33

> Data dari konfigurasi CPE di NVD.

Referensi dan perbaikan

Sumber: NVD · CVE.org · EPSS. Halaman ini disusun otomatis dari data tersebut; pembaruan terakhir 5 Okt 2026, 20:10 WITA. Kalau sistem di Perangkat Daerah memakai produk ini dan butuh bantuan, laporkan lewat kanal pelaporan.